Skip to main content
Premium Trial:

Request an Annual Quote

Compugen and Biosite Expand Dx-Development Alliance

NEW YORK (GenomeWeb News) — Biosite will have access to more of Compugen’s diagnostic and immunoassay biomarkers under a renewed and expanded partnership and licensing agreement, Compugen said today.
 
In June 2005 the companies penned an alliance to develop and commercialize immunoassay-based diagnostics for cardiovascular and oncology indications based on several of Compugen’s gene targets.
 
Under the new agreement, which covers the same indications, Compugen will receive milestone payments and royalties from product sales that resulted from its contribution.
 
Compugen also said it will hold the rights to therapeutic applications of targets and antibodies associated with them.

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.